TY - JOUR
T1 - Management of primary ciliary dyskinesia in European children
T2 - recommendations and clinical practice
AU - Strippoli, Marie-Pierre F
AU - Frischer, Thomas
AU - Barbato, Angelo
AU - Snijders, Deborah
AU - Maurer, Elisabeth
AU - Lucas, Jane S A
AU - Eber, Ernst
AU - Karadag, Bulent
AU - Pohunek, Petr
AU - Zivkovic, Zorica
AU - Escribano, Amparo
AU - O'Callaghan, Chris
AU - Bush, Andrew
AU - Kuehni, Claudia E
AU - ERS Task Force onPrimary Ciliary Dyskinesia in Children
A2 - Nielsen, Kim Gjerum
PY - 2012/6
Y1 - 2012/6
N2 - The European Respiratory Society Task Force on primary ciliary dyskinesia (PCD) in children recently published recommendations for diagnosis and management. This paper compares these recommendations with current clinical practice in Europe. Questionnaires were returned by 194 paediatric respiratory centres caring for PCD patients in 26 countries. In most countries, PCD care was not centralised, with a median (interquartile range) of 4 (2-9) patients treated per centre. Overall, 90% of centres had access to nasal or bronchial mucosal biopsy. Samples were analysed by electron microscopy (77%) and ciliary function tests (57%). Nasal nitric oxide was used for screening in 46% of centres and saccharine tests in 36%. Treatment approaches varied widely, both within and between countries. European region, size of centre and the country's general government expenditure on health partly defined availability of advanced diagnostic tests and choice of treatments. In conclusion, we found substantial heterogeneity in management of PCD within and between countries, and poor concordance with current recommendations. This demonstrates how essential it is to standardise management and decrease inequality between countries. Our results also demonstrate the urgent need for research: to simplify PCD diagnosis, to understand the natural history and to test the effectiveness of interventions.
AB - The European Respiratory Society Task Force on primary ciliary dyskinesia (PCD) in children recently published recommendations for diagnosis and management. This paper compares these recommendations with current clinical practice in Europe. Questionnaires were returned by 194 paediatric respiratory centres caring for PCD patients in 26 countries. In most countries, PCD care was not centralised, with a median (interquartile range) of 4 (2-9) patients treated per centre. Overall, 90% of centres had access to nasal or bronchial mucosal biopsy. Samples were analysed by electron microscopy (77%) and ciliary function tests (57%). Nasal nitric oxide was used for screening in 46% of centres and saccharine tests in 36%. Treatment approaches varied widely, both within and between countries. European region, size of centre and the country's general government expenditure on health partly defined availability of advanced diagnostic tests and choice of treatments. In conclusion, we found substantial heterogeneity in management of PCD within and between countries, and poor concordance with current recommendations. This demonstrates how essential it is to standardise management and decrease inequality between countries. Our results also demonstrate the urgent need for research: to simplify PCD diagnosis, to understand the natural history and to test the effectiveness of interventions.
KW - Child
KW - Child, Preschool
KW - Cystic Fibrosis/diagnosis
KW - Europe
KW - Female
KW - Health Care Surveys
KW - Humans
KW - Kartagener Syndrome/diagnosis
KW - Male
KW - Nitric Oxide/analysis
KW - Practice Guidelines as Topic
KW - Respiratory Mucosa/pathology
KW - Saccharin
KW - Surveys and Questionnaires
KW - Treatment Outcome
UR - https://www.scopus.com/pages/publications/84861893453
U2 - 10.1183/09031936.00073911
DO - 10.1183/09031936.00073911
M3 - Journal article
C2 - 22282549
SN - 0903-1936
VL - 39
SP - 1482
EP - 1491
JO - The European respiratory journal
JF - The European respiratory journal
IS - 6
ER -